Efficacy and Safety of Insulin Lispro in Geriatric Patients with Type 2 Diabetes: a Retrospective Analysis of Seven Randomized Controlled Clinical Trials

Overview

Journal Aging Clin Exp Res

Publisher Springer

Specialty Geriatrics

Date 2013 Aug 21

PMID 23959960

Citations 1

Authors

Bradley H Curtis

Tina M Rees

Kim A Gaskins

Justo Sierra-Johnson

Rong Liu

Honghua H Jiang

John H Holcombe

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Glycemic control in geriatric patients with type 2 diabetes (T2DM) remains clinically challenging. The objective of this study was to compare the safety and efficacy of insulin lispro in patients C65 years (geriatric) to those\65 years (non-geriatric), using a metaanalysis of randomized controlled clinical trials (RCT).

Methods: This is a retrospective analysis of predefined endpoints from an integrated database of seven RCTs of T2DM patients treated with insulin lispro. The primary efficacy measure tested the non-inferiority of insulin lispro (geriatric vs. non-geriatric; non-inferiority margin 0.4 %) in terms of hemoglobin A1c (HbA1c) change from baseline to Month 3 (N = 1,525), with change from baseline to Month 6 as a supportive analysis (N = 885). Changes in HbA1c from baseline were evaluated with an analysis of covariance model. Secondary measures included incidence and rate of hypoglycemia, and incidence of cardiovascular events.

Results: Mean change in HbA1c from baseline to Month 3 was similar for geriatric (-0.97 %) and non-geriatric patients (-1.05 %); least-square (LS) mean difference (95 % CI) was 0.02 % (-0.11, 0.15 %; p = 0.756). Similar results were observed in patients treated up to Month 6; LS mean difference (95 % CI) was 0.07 % (-0.12, 0.26 %; p = 0.490). Decrease in HbA1c from baseline to Months 3 and 6 was non-inferior in geriatric compared with non-geriatric patients. There were no significant differences in the incidence and the rate of hypoglycemia, incidence of cardiovascular events, or other serious adverse events including malignancy, post-baseline between the two cohorts.

Conclusion: Key measures of efficacy and safety in geriatric patients with T2DM were not significantly different from non-geriatric patients when utilizing insulin lispro. Insulin lispro may be considered a safe and efficacious therapeutic option for the management of T2DM in geriatric patients.

Citing Articles

HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs.

Fritsche A, Anderten H, Pfohl M, Pscherer S, Borck A, Pegelow K BMJ Open Diabetes Res Care. 2019; 7(1):e000668.

PMID: 31423316 PMC: 6688703. DOI: 10.1136/bmjdrc-2019-000668.

References

Raz I, Wilson P, Strojek K, Kowalska I, Bozikov V, Gitt A . Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009; 32(3):381-6. PMC: 2646013. DOI: 10.2337/dc08-1671. View

Lee S, Boscardin W, Cenzer I, Huang E, Rice-Trumble K, Eng C . The risks and benefits of implementing glycemic control guidelines in frail older adults with diabetes mellitus. J Am Geriatr Soc. 2011; 59(4):666-72. PMC: 3764989. DOI: 10.1111/j.1532-5415.2011.03362.x. View

Neumiller J, Setter S . Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2010; 7(6):324-42. DOI: 10.1016/j.amjopharm.2009.12.002. View

Bourdel-Marchasson I, Schweizer A, Dejager S . Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract (1995). 2011; 39(1):7-21. DOI: 10.3810/hp.2011.02.369. View

Leinung M, Thompson S, Nardacci E . Benefits of continuous glucose monitor use in clinical practice. Endocr Pract. 2010; 16(3):371-5. DOI: 10.4158/EP09287.OR. View

Munshi M, Segal A, Suhl E, Staum E, DesRochers L, Sternthal A . Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med. 2011; 171(4):362-4. PMC: 4123960. DOI: 10.1001/archinternmed.2010.539. View

Pornet C, Bourdel-Marchasson I, Lecomte P, Eschwege E, Romon I, Fosse S . Trends in the quality of care for elderly people with type 2 diabetes: the need for improvements in safety and quality (the 2001 and 2007 ENTRED Surveys). Diabetes Metab. 2011; 37(2):152-61. DOI: 10.1016/j.diabet.2011.02.001. View

Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts V, Thorsteinsson B . Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006; 28(10):1569-81. DOI: 10.1016/j.clinthera.2006.10.020. View

Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober S . A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes. Diabet Med. 2010; 27(2):181-8. DOI: 10.1111/j.1464-5491.2009.02899.x. View

10.

Constans T . Plasma glucose goals and therapeutic management in elderly diabetic patients. Diabetes Metab. 2006; 31 Spec No 2:5S58-5S61. DOI: 10.1016/s1262-3636(05)73652-1. View

11.

. Standards of medical care in diabetes--2012. Diabetes Care. 2011; 35 Suppl 1:S11-63. PMC: 3632172. DOI: 10.2337/dc12-s011. View

12.

Anderson Jr J, Brunelle R, Koivisto V, Trautmann M, Vignati L, DiMarchi R . Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther. 1997; 19(1):62-72. DOI: 10.1016/s0149-2918(97)80073-2. View

13.

Bastyr 3rd E, Huang Y, Brunelle R, Vignati L, Cox D, Kotsanos J . Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro. Diabetes Obes Metab. 2001; 2(1):39-46. DOI: 10.1046/j.1463-1326.2000.00066.x. View

14.

DeWitt D, Hirsch I . Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003; 289(17):2254-64. DOI: 10.1001/jama.289.17.2254. View

15.

Stahl M, Berger W . Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med. 1999; 16(7):586-90. DOI: 10.1046/j.1464-5491.1999.00110.x. View

16.

Anderson Jr J, Brunelle R, Keohane P, Koivisto V, Trautmann M, Vignati L . Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med. 1997; 157(11):1249-55. View

17.

Schwartz S, Kohl B . Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia. Mayo Clin Proc. 2010; 85(12 Suppl):S15-26. PMC: 2996166. DOI: 10.4065/mcp.2010.0468. View

18.

Bastyr 3rd E, Johnson M, Trautmann M, Anderson Jr J, Vignati L . Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther. 1999; 21(10):1703-14. DOI: 10.1016/s0149-2918(99)80049-6. View

19.

Spain M, Edlund B . Introducing insulin into diabetes management: transition strategies for older adults. J Gerontol Nurs. 2011; 37(4):10-5. DOI: 10.3928/00989134-20110309-01. View

20.

Zafon C, Creus C . A comparison on insulin regimen treatment of elderly (>70 years) and younger (<70 years) type 2 diabetic patients in actual clinical practice. Acta Diabetol. 2011; 50(1):33-7. DOI: 10.1007/s00592-011-0289-6. View